Grant awards set stage for next seven years of science-driven HIV clinical research.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, announced the clinical investigators and institutions that will lead four NIH HIV clinical trials networks over the next seven years to conduct the innovative, efficient clinical research needed to accelerate progress against the HIV pandemic. NIAID also awarded grants to 35 U.S. and international institutions selected as HIV clinical trials units (CTUs). NIAID and co-funding NIH Institutes intend to provide approximately $375.3 million in the first year to support the networks.
Rachel Presti, MD, associate professor of medicine, infectious diseases is the Principal Investigator, NIH – AIDS Clinical Trials Unit at Washington University School of Medicine and also the Medical Director of the Infectious Diseases Clinical Research Unit (ID CRU). The ACTU serves as a clinical research site to Vanderbilt University Medical Center HIV Clinical Trials Unit (CTU) led by David W. Haas, MD, professor of medicine at Vanderbilt.
To learn more about these new awards and the process to refine NIH’s HIV clinical trials networks, see NIAID’s Refining the HIV Clinical Trials Enterprise website.